Next Article in Journal / Special Issue
Tumor Metabolism of Malignant Gliomas
Previous Article in Journal
The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation
Previous Article in Special Issue
Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
Cancers 2013, 5(4), 1456-1468; doi:10.3390/cancers5041456

Bevacizumab for Glioblastoma—A Promising Drug or Not?

1 Department of Neurosurgery, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan 2 Department of Neuro-Oncology/Neurosurgery, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama-ken 350-1298, Japan
* Author to whom correspondence should be addressed.
Received: 11 October 2013 / Accepted: 24 October 2013 / Published: 7 November 2013
(This article belongs to the Special Issue Glioblastoma)
View Full-Text   |   Download PDF [343 KB, uploaded 7 November 2013]


Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond.
Keywords: bevacizumab; glioblastoma; chemotherapy bevacizumab; glioblastoma; chemotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Nagane, M.; Nishikawa, R. Bevacizumab for Glioblastoma—A Promising Drug or Not? Cancers 2013, 5, 1456-1468.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert